Clinical Trial: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06927349) titled 'A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.' on April 07.

Brief Summary: This is an open label Phase 1, First in Human trial designed to evaluate the safety, tolerability pharmacokinetics, preliminary efficacy of BA1301 in participants with advanced solid tumors.

Study Start Date: Jan. 11, 2023

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumours

Intervention: DRUG: BA1301

BA1301 is administered intravenously once every three weeks.

Recruitment Status: RECRUITING

Sponsor: Shandong Boan Biotechnology Co., Ltd

Published by HT Digital Content...